← Leaderboards
Vladimir M Kolenko
Fox Chase Cancer Center
$4,356,950
Attributed
$4,445,554
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $924.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,445,554 · 8
By mechanism
R01$2,758,410 · 2
R21$966,790 · 2
R03$720,354 · 4
Top collaborators
- Ross Wang1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoNovel TherapeuticsTumorMediatingResistanceMalignant NeoplasmsMalignant Neoplasm Of ProstateCancer CellIn VitroGrowthCessation Of LifeAndrogensProteinsCellsRegimenXenograft ModelMouse ModelInsightResearch StudyProstateProstate Cancer TherapyPathway InteractionsProtein ExpressionMale
Grant awards (19)
Targeting p300/CBP in renal cell carcinoma$483,395
R21 · FY2025 · CA · contact PI
NPC1 as a novel therapeutic target in ccRCC$263,670
R21 · FY2025 · CA · contact PI
Targeting the Undruggable in Castration-Resistant Prostate Cancer with FTDR-Stapled Peptide Probes$177,209
R03 · FY2025 · CA
NPC1 as a novel therapeutic target in ccRCC$219,725
R21 · FY2024 · CA · contact PI
The role of cholesterol homeostasis in enzalutamide resistance$93,500
R03 · FY2021 · CA · contact PI
The role of cholesterol homeostasis in enzalutamide resistance$93,500
R03 · FY2020 · CA · contact PI
LDL cholesterol and TKI resistance in renal cell carcinoma$91,500
R03 · FY2018 · CA · contact PI
LDL cholesterol and TKI resistance in renal cell carcinoma$91,500
R03 · FY2017 · CA · contact PI
Therapeutics of XIAP Degradation by Zinc Chelators$303,948
R01 · FY2013 · CA · contact PI
Piperlongumine: A Novel Inhibitor of Androgen Receptor Signaling$83,895
R03 · FY2013 · CA · contact PI
Therapeutics of XIAP Degradation by Zinc Chelators$323,055
R01 · FY2012 · CA · contact PI
Piperlongumine: A Novel Inhibitor of Androgen Receptor Signaling$89,250
R03 · FY2012 · CA · contact PI
Therapeutics of XIAP Degradation by Zinc Chelators$316,103
R01 · FY2011 · CA · contact PI
Therapeutics of XIAP Degradation by Zinc Chelators$325,879
R01 · FY2010 · CA · contact PI
Therapeutics of XIAP Degradation by Zinc Chelators$325,879
R01 · FY2009 · CA · contact PI
Role of Zinc in Prostate Carcinogenesis$284,831
R01 · FY2008 · CA · contact PI
Role of Zinc in Prostate Carcinogenesis$284,831
R01 · FY2007 · CA · contact PI
Role of Zinc in Prostate Carcinogenesis$293,338
R01 · FY2006 · CA · contact PI
Role of Zinc in Prostate Carcinogenesis$300,546
R01 · FY2005 · CA